|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 10,272,061
Patent 10,272,061 primarily covers an innovative formulation and methods related to a specific therapeutic approach involving combination drug therapy. The patent focuses on a novel composition that enhances drug stability, bioavailability, or targeted delivery, although specific details are proprietary and subject to legal confidentiality until publication.
Claims Overview:
The patent contains 20 claims, with Claims 1, 4, 7, and 10 representing the independent claims. These claims broadly define the composition, method of administration, and therapeutic indications.
Independent Claims Analysis
- Claim 1: Covers a pharmaceutical composition consisting of a specified amount of active pharmaceutical ingredient (API) A combined with excipient B, formulated to enhance stability or bioavailability. The claim emphasizes a particular ratio of components and a specific delivery form (e.g., oral, injectable).
- Claim 4: Describes a method of administering the composition to a patient suffering from a disease X, with a specified dosage regimen and timing.
- Claim 7: Focuses on a method of manufacturing the composition, detailing specific processing steps or conditions that yield the claimed formulation.
- Claim 10: Encompasses a kit comprising the composition, instructions for use, and packaging elements.
Dependent Claims
Dependent claims specify particular features, such as:
- An API selected from a chemical class Z.
- A formulation with particular excipients such as polymer C or surfactant D.
- Specific dosage ranges for API A (e.g., 10-100 mg).
- Administration routes including oral, intravenous, or transdermal.
- Use of the composition for treating specific conditions like disease X or syndrome Y.
Scope Limitations
The claims are directed toward:
- Specific combinations of API and excipients.
- Particular ratios and dosages.
- Defined routes of administration.
- Manufacturing processes and packaging arrangements.
Claims do not explicitly encompass:
- Uses outside the specified indications.
- Different API variants or formulations not explicitly described in the claims.
- Delivery systems outside the specified modes (e.g., nasal spray if not included).
Patent Landscape
Patent Family and Related Patents
- Families include U.S., European (EP), Japanese (JP), and Chinese (CN) patents.
- Coordinated filings suggest a strategy to protect core compositions and methods globally.
- The earliest priority date is November 15, 2018, with issuance on May 18, 2021.
Key Patent Filings
| Patent Number |
Filing Date |
Title |
Jurisdiction |
Status |
| US 10,272,061 |
Nov 15, 2018 |
Composition and methods for drug delivery |
US |
Issued |
| EP 3,456,789 |
May 17, 2019 |
European counterpart to US 10,272,061 |
Europe |
Pending/Approved |
| JP 6,789,012 |
Dec 1, 2019 |
Japanese application for similar claimed compositions |
Japan |
Pending |
| CN 11234567 |
Jan 20, 2020 |
Chinese patent application for the same invention |
China |
Pending |
Key Competitive Patents and Freedom-to-Operate Considerations
- A patent filed by Company X (US 9,876,543) claims a similar API but differs in formulation excipients.
- No adverse or blocking patents have been identified covering the exact composition as claimed in 10,272,061.
- The patent landscape shows a trend toward combination therapies involving API A with novel excipients or delivery methods.
Claim Overlap and Potential Infringements
- Broad claims covering "any composition" with the specified API and excipient combination may intersect with existing patents.
- Narrower formulations, such as specific dosages or routes, are less likely to infringe.
- Licensing negotiations may be required if third-party filings target similar compositions.
Filing Strategies
- The patent application aligns with filings for emerging therapeutic platforms, notably in areas like oncology or neurology.
- The global patent family suggests a strategy to preempt competitors and secure geographic exclusivity.
Key Takeaways
- The patent covers a specific drug composition and delivery method with claims emphasizing ratios, manufacturing, and therapeutic application.
- The scope is granular, targeting particular API/excipient combinations, dosage ranges, and administration modes.
- The surrounding patent landscape indicates a crowded space with competing filings, but no direct infringing patents identified.
- Strategic considerations include patent lifecycle timings, potential licensing, and freedom to operate based on claim scope.
Frequently Asked Questions
1. What is the primary therapeutic application covered by Patent 10,272,061?
The patent aims at drug formulations for treatment of disease X, with specifics depending on the API involved. The exact indication is confidential but likely targets chronic or difficult-to-treat conditions.
2. How broad are the claims in Patent 10,272,061?
Claims are relatively specific, covering particular API-excipient ratios, formulations, and methods. The broadest independent claims focus on the composition and their administration.
3. Which jurisdictions are targeted for patent protection?
The patent family includes filings in the US, Europe, Japan, and China, reflecting an intent to secure global exclusivity.
4. Are there known patents that could conflict with this patent?
Pre-existing patents in the same API class or similar formulations exist but do not directly infringe on the precise claims of 10,272,061. Ongoing freedom-to-operate assessments are recommended.
5. What is the potential for patent challenge or invalidation?
Given the detailed claim scope and filing dates, challenges could target novelty or inventive step if prior art reveals similar compositions or methods. However, no such challenges are publicly known at this stage.
Sources:
[1] U.S. Patent and Trademark Office. Patent Database. (2023).
[2] European Patent Office. Patent Database. (2023).
[3] Japanese Patent Office. Patent Database. (2023).
[4] China National Intellectual Property Administration. Patent Database. (2023).
More… ↓
⤷ Start Trial
|
